샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536116

세계 출혈성 뇌졸중 치료제 시장

Hemorrhagic Stroke Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 287 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

출혈성 뇌졸중 치료제 세계 시장은 2030년까지 13억 달러에 달할 전망입니다.

2023년에 11억 달러로 추정되는 출혈성 뇌졸중 치료제 세계 시장은 분석 기간 2023-2030년에 CAGR 2.5%로 성장하고 2030년에는 13억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 항고혈압제는 CAGR 3.1%로 성장을 지속하고, 분석 기간 종료시에는 6억 3,430만 달러에 달할 것으로 예측됩니다. 항응고제 부문의 성장률은 분석 기간 동안 CAGR 2.4%로 추정됩니다.

미국 시장은 추정 2억 9,550만 달러, 중국은 CAGR 5.0%로 성장 예측

미국 출혈성 뇌졸중 치료제 시장은 2023년 2억 9,550만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2023-2030년간 CAGR 5.0%로 성장을 지속하여 2030년에는 2억 5,700만 달러 규모에 이를 것으로 예측되고 있습니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.6%와 1.8%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 1.2%로 성장할 것으로 예측됩니다.

세계 출혈성 뇌졸중 치료제 시장 - 주요 동향 및 촉진요인 요약

뇌내 출혈을 특징으로 하는 출혈성 뇌졸중은 생명을 위협하는 심각한 질환으로, 급한 의료 개입이 필요합니다. 출혈성 뇌졸중의 관리는 주로 출혈의 억제, 두개 내압의 감소, 추가적인 신경 장애의 예방에 중점을 둡니다. 출혈성 뇌졸중 치료제는 이 치료 패러다임에서 중요한 역할을 합니다. 주요 약물에는 출혈성 뇌졸중의 흔한 원인인 고혈압을 관리하기 위한 강압제와 혈액응고를 촉진하고 환자를 안정시키는 지혈제가 포함됩니다. 또한 출혈과 부종으로 인한 뇌 손상을 최소화하는 신경보호제도 연구되고 있습니다. 시간이 지남에 따라 효과적인 약리학적 개입은 환자의 결과를 현저하게 개선하고 사망률을 감소시키기 때문에 이러한 약물의 개발은 매우 중요합니다.

최근 출혈성 뇌절증 치료제 분야의 동향은 효능과 안전성 프로파일의 개선을 목표로 하는 혁신적인 R&D에 의해 두드러지고 있습니다. 나노입자 및 표적 전달 메커니즘과 같은 새로운 약물 전달 시스템은 치료의 정확성과 효능을 높이기 위해 연구되었습니다. 이러한 진보는 부작용을 최소화하고 치료 효과를 극대화하는 데 특히 중요합니다. 또한 MRI 및 CT 스캔과 같은 고급 이미징 기술을 약물 투여 프로토콜과 통합하여 개별 환자의 요구에 맞게 치료할 수 있어 뇌졸중 출혈 관리의 전반적인 효능이 향상되었습니다. 임상시험과 현재 진행중인 조사에서는 출혈성 뇌졸중의 복잡한 병태생리에 대처하고 회복률을 향상시키는 것을 목표로 신약 후보와 조합의 연구가 계속되고 있습니다.

출혈성 뇌졸중 치료제 시장의 성장은 고령화에 의한 뇌졸중 발병률 증가, 고혈압 및 관련 질환의 유병률 증가, 의료 기술의 진보 등 여러 요인에 의해 견인되고 있습니다. 보다 효과적이고 안전한 치료에 대한 수요는 새로운 약리학적 접근과 약물 전달 시스템의 연구를 뒷받침하고 있습니다. 또한 뇌졸중의 증상에 대한 인식이 높아지고 신속한 치료가 중요하다는 것이 조기 진단과 조기 개입으로 이어지는 것도 이러한 의약품 시장을 견인하고 있습니다. 또한 유망한 새로운 치료제에 대한 규제 당국의 지원과 승인의 가속화도 시장 확대에 기여하고 있습니다. 게다가, 특히 신흥 시장에서의 건강 관리 지출 증가는 첨단 치료에 대한 접근을 확대하고 시장 성장의 원동력이 되고 있습니다. 이러한 동향이 계속되는 가운데 출혈성 뇌졸중 치료제 시장은 지속적인 기술 혁신과 보다 나은 치료법을 요구하는 환자층의 확대로 지속적인 성장이 예상됩니다.

조사 대상 기업 예(전 86건)

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr Reddy's Laboratories Ltd
  • J&J MedTech
  • Lupin Limited
  • Novartis AG
  • Op2Lysis
  • Pfizer Inc.
  • Sanofi-aventis US LLC(Winthrop)
  • Teva Pharmaceutical Industries Ltd;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.08.29

Global Hemorrhagic Stroke Drugs Market to Reach US$1.3 Billion by 2030

The global market for Hemorrhagic Stroke Drugs estimated at US$1.1 Billion in the year 2023, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2023-2030. Antihypertensives, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$634.3 Million by the end of the analysis period. Growth in the Anticoagulants segment is estimated at 2.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$295.5 Million While China is Forecast to Grow at 5.0% CAGR

The Hemorrhagic Stroke Drugs market in the U.S. is estimated at US$295.5 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$257.0 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Hemorrhagic Stroke Drugs Market - Key Trends and Drivers Summarized

Hemorrhagic stroke, characterized by bleeding within the brain, is a severe and life-threatening condition that requires immediate medical intervention. The management of hemorrhagic stroke primarily focuses on controlling the bleeding, reducing intracranial pressure, and preventing further neurological damage. Hemorrhagic stroke drugs play a crucial role in this treatment paradigm. Key medications include antihypertensives to manage high blood pressure, which is a common cause of hemorrhagic strokes, and hemostatic agents that help to promote blood clotting and stabilize the patient. Additionally, neuroprotective agents are being investigated to minimize brain damage caused by bleeding and swelling. The development of these drugs is critical, as timely and effective pharmacological intervention can significantly improve patient outcomes and reduce mortality rates.

Recent advancements in the field of hemorrhagic stroke drugs have been marked by innovative research and development efforts aimed at improving efficacy and safety profiles. Novel drug delivery systems, such as nanoparticles and targeted delivery mechanisms, are being explored to enhance the precision and effectiveness of treatments. These advancements are particularly important in minimizing side effects and maximizing therapeutic benefits. Furthermore, the integration of advanced imaging techniques, like MRI and CT scans, with drug administration protocols is helping to tailor treatments to individual patient needs, thus improving the overall effectiveness of hemorrhagic stroke management. Clinical trials and ongoing research continue to explore new drug candidates and combinations, aiming to address the complex pathophysiology of hemorrhagic strokes and improve recovery rates.

The growth in the hemorrhagic stroke drugs market is driven by several factors, including the rising incidence of stroke due to an aging population, increasing prevalence of hypertension and related conditions, and advancements in medical technology. The demand for more effective and safer treatments is propelling research into new pharmacological approaches and drug delivery systems. Additionally, greater awareness of stroke symptoms and the importance of rapid treatment is leading to earlier diagnosis and intervention, which in turn drives the market for these drugs. Regulatory support and the fast-tracking of approvals for promising new therapies are also contributing to market expansion. Furthermore, increasing healthcare expenditure, particularly in emerging markets, is expanding access to advanced treatments and fueling market growth. As these trends continue, the hemorrhagic stroke drugs market is expected to experience sustained growth, driven by ongoing innovations and an expanding patient base seeking better treatment options.

Select Competitors (Total 86 Featured) -

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr Reddy's Laboratories Ltd
  • J&J MedTech
  • Lupin Limited
  • Novartis AG
  • Op2Lysis
  • Pfizer Inc.
  • Sanofi-aventis U.S. LLC (Winthrop)
  • Teva Pharmaceutical Industries Ltd;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Hemorrhagic Stroke Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Stroke Drives Demand for Advanced Therapies
    • Technological Innovations Propel Growth in Hemorrhagic Stroke Drugs Market
    • Aging Population Expands Addressable Market Opportunity
    • Increasing Prevalence of Hypertension Spurs Market Expansion
    • Novel Drug Delivery Systems Strengthen Business Case for Advanced Treatments
    • Integration of Imaging Techniques with Drug Protocols Accelerates Adoption
    • Greater Awareness of Stroke Symptoms Generates Demand for Early Intervention
    • Growing Healthcare Expenditure in Emerging Markets Expands Market Reach
    • Enhanced Precision and Efficacy of Treatments Drive Market Evolution
    • Advances in Neuroprotective Agents Spur Growth and Innovation
    • Increased Focus on Personalized Medicine Drives Adoption of Tailored Therapies
    • Evolution of Patient Management Protocols Sustains Market Expansion
    • Increasing Use of AI and Machine Learning in Drug Development Generates New Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hemorrhagic Stroke Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hemorrhagic Stroke Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hemorrhagic Stroke Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antihypertensives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antihypertensives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antihypertensives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Anticoagulants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Anticoagulants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Ambulatory Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Ambulatory Surgical Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other End Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other End Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other End Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemorrhagic Stroke Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hemorrhagic Stroke Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hemorrhagic Stroke Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hemorrhagic Stroke Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hemorrhagic Stroke Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hemorrhagic Stroke Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hemorrhagic Stroke Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hemorrhagic Stroke Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Hemorrhagic Stroke Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hemorrhagic Stroke Drugs by Drug Class - Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Hemorrhagic Stroke Drugs by Drug Class - Percentage Breakdown of Value Sales for Antihypertensives, Anticoagulants, Diuretics, Anticonvulsants and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Hemorrhagic Stroke Drugs by End-Use - Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Hemorrhagic Stroke Drugs by End-Use - Percentage Breakdown of Value Sales for Hospital End-Use, Ambulatory Surgical Centers End-Use and Other End Uses for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제